Varonis stock rebounds after 11% slide as fresh shareholder lawsuit filing hits tape
24 February 2026
1 min read

Varonis stock rebounds after 11% slide as fresh shareholder lawsuit filing hits tape

New York, February 24, 2026, 09:41 EST — Regular session

  • Varonis Systems gained roughly 2.4%, bouncing back a bit after sliding 11% on Monday.
  • A securities class action has been filed, the law firm announced, with a lead-plaintiff deadline of March 9.
  • All eyes remain on the company’s SaaS transition and its 2026 forecast, following the earlier guidance upheaval that rattled investors.

Shares of Varonis Systems Inc bounced back about 2.4% to $21.59 Tuesday morning, clawing back from a sharp drop the previous session. The move came as the data-security firm faced fresh attention from yet another set of shareholder lawsuits.

The legal update arrives just as Varonis is pushing to recalibrate investor expectations, caught mid-pivot to software-as-a-service (SaaS) subscriptions and rolling out fresh metrics that Wall Street is watching. SaaS, for the record, refers to software provided online, typically sold through subscriptions.

Shares have swung since early February, after the company released its 2026 guidance and pointed to challenges as clients transition from older self-hosted offerings to SaaS.

Bernstein Liebhard announced that a shareholder has lodged a securities class action targeting Varonis, covering investors who picked up Varonis common shares from Feb. 4, 2025 through Oct. 28, 2025.

Hagens Berman, for its part, flagged a March 9, 2026 window for investors to seek lead-plaintiff status in a securities class action it says targets the company and certain executives.

Varonis shares slid 11.0% on Monday, landing at $21.08.

The stock traded between $20.68 and $21.67 on Tuesday, starting the session at $21.12, Investing.com data show.

Varonis, a software provider focused on helping companies secure sensitive data, has been making its case to investors around subscription-based annual recurring revenue (ARR)—a key metric for the software sector’s steady income. On the Feb. 3 earnings call, CFO and COO Guy Melamed singled out “SaaS ARR, excluding conversions, is really the most important KPI,” marking it as the performance measure to watch. Investing.com

The company pointed out to investors that its U.S. federal and state government clients make up the “largest cohort” unlikely to move over to SaaS. Because of that, it’s bracing for a headwind of $30 million to $50 million in 2026. Investing.com

Varonis operates in a packed segment of cybersecurity and data governance. Companies here are bundling protection tools, with customers consolidating their vendor lists and relying more heavily on major cloud platforms.

The constant threat of litigation could weigh on the stock, particularly if additional firms serve notices or court dates begin colliding with sales cycles and renewals.

Eyes are on fresh court filings ahead of the March 9 lead-plaintiff cutoff, with investors also bracing for the company’s next updates — its earnings report is on the calendar for early May.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Tesla Keeps Bitcoin Unchanged, Posts $112M Q2 Loss
    July 22, 2026, 8:52 PM EDT. Tesla Inc. (NASDAQ: TSLA) left its Bitcoin holdings unaltered at 11,509 BTC through the second quarter, booking a $112 million after-tax loss as Bitcoin fell roughly 14%. Bitcoin slid from $83,000 to near $58,000 for the period, but Tesla continued to refrain from any Bitcoin transactions since 2022. The firm logged $28.2 billion revenue and $1.11 billion GAAP net income in Q2, with Tesla shares trading at $374.01 and Bitcoin at $65,922.
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Previous Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus
Next Story

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus